Corvus Pharmaceuticals, Inc. (CRVS): Depreciation & Amortization
$105.0K
Year ended 2025-12-31
$117.0K
Trailing 12 months to 2026-06-30
-34.1%
3-year compound annual growth
-30.2%
5-year compound annual growth
-3.4%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $105.0K | +23.5% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $85.0K | -43.7% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $151.0K | -58.9% | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | $367.0K | -20.2% | 2025-03-25, From 2022-01-01 |
| 2021-12-31 | $460.0K | -27.2% | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | $632.0K | -14.9% | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | $743.0K | -12.3% | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | $847.0K | +0.6% | 2021-03-25, From 2018-01-01 |
| 2017-12-31 | $842.0K | +41.8% | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | $594.0K | +301.4% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $148.0K | n/a | 2018-03-01, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $105.0K | +23.5% |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $240.0K | -2.4% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $0 | -100.0% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $16.3K | +49.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.15M | -15.4% |
| Adagene Inc. (ADAG) | 2025-12-31 | $438.9K | -39.3% |
| Rallybio Corp (RLYB) | 2025-12-31 | $92.0K | -29.8% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $2.06M | +18.3% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $447.0K | -2.6% |
Compare CRVS, IXHL, SPRO, CNTX side by side · Screen every company in Pharmaceutical Preparations ↗